Virginia M.‐y. Lee

Virginia M.‐y. Lee's AcademicInfluence.com Rankings

Virginia M.‐y. Lee

Biology

#2562

World Rank

#4040

Historical Rank

Neuroscience

#220

World Rank

#232

Historical Rank

biology Degrees

Download Badge

Biology

Virginia M.‐y. Lee's Degrees

PhD Biochemistry University of California, San Francisco

Why Is Virginia M.‐y. Lee Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Virginia M.‐y. Lee's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (2006) (5319)
α-Synuclein in Lewy bodies (1997) (4852)
Diagnosis and management of dementia with Lewy bodies (2005) (3346)
Alpha-synuclein in Lewy bodies. (1997) (2847)
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders (2007) (1898)
Diagnosis and management of dementia with Lewy bodies (2017) (1606)
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. (2000) (1546)
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. (1998) (1493)
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model (2007) (1409)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death (2011) (1200)
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease (2001) (1113)
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS (2010) (1095)
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides (2003) (1067)
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration (2007) (1007)
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein (2002) (974)
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. (1998) (951)
Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations (2007) (887)
A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* (2001) (882)
Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons (2000) (882)
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice (2012) (871)
Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice (2005) (828)
Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding (1993) (810)
A harmonized classification system for FTLD-TDP pathology (2011) (781)
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques (2009) (756)
Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells (1992) (754)
Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis (2013) (747)
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis (2008) (701)
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs (2004) (688)
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls (2013) (671)
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein (1998) (625)
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies (2013) (609)
Spreading of pathology in neurodegenerative diseases: a focus on human studies (2015) (599)
The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging (1999) (578)
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. (2002) (577)
Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform (1999) (571)
Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons (2013) (567)
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. (2002) (559)
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease (2000) (557)
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration (2011) (557)
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau (1994) (555)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. (1995) (543)
The acetylation of tau inhibits its function and promotes pathological tau aggregation. (2011) (543)
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. (2003) (539)
Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * (1999) (534)
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. (2002) (530)
Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation* (2008) (527)
Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy (2013) (525)
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases (2014) (511)
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. (1999) (511)
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. (1998) (497)
Epitopes that span the tau molecule are shared with paired helical filaments (1988) (485)
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. (1998) (478)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease (2012) (461)
Frontotemporal dementia: Clinicopathological correlations (2006) (456)
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies (2009) (448)
Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery (2006) (444)
Synucleinopathies: clinical and pathological implications. (2001) (443)
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. (1992) (442)
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. (1993) (437)
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. (2007) (436)
Mechanism of Ca2+ Disruption in Alzheimer's Disease by Presenilin Regulation of InsP3 Receptor Channel Gating (2008) (434)
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. (1999) (417)
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. (1996) (409)
Neuropathologic substrates of Parkinson disease dementia (2012) (406)
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies (2009) (404)
Amyotrophic lateral sclerosis—a model of corticofugal axonal spread (2013) (395)
Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration (2008) (392)
TAR DNA-binding protein 43 in neurodegenerative disease (2010) (390)
Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. (2006) (385)
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury (2004) (378)
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases (2007) (378)
Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity (2000) (369)
Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult (2001) (369)
Axonal transport defects: a common theme in neurodegenerative diseases (2005) (366)
Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation (2017) (363)
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? (2003) (359)
Transplantation of Cryopreserved Human Embryonal Carcinoma-Derived Neurons (NT2N Cells) Promotes Functional Recovery in Ischemic Rats (1998) (359)
DLB and PDD boundary issues (2007) (351)
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein (2000) (346)
Repetitive Mild Brain Trauma Accelerates Aβ Deposition, Lipid Peroxidation, and Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Amyloidosis (2002) (344)
Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans (2007) (344)
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated (2018) (338)
Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies (2008) (337)
Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau (*) (1995) (334)
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease (2013) (332)
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice (2012) (329)
Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons (2000) (328)
A yeast functional screen predicts new candidate ALS disease genes (2011) (327)
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics (2007) (321)
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases (2002) (318)
Pathological changes in olfactory neurons in patients with Alzheimer's disease (1989) (315)
In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice (2011) (310)
Therapeutic modulation of eIF2α-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models (2013) (310)
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. (2006) (309)
Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation (1997) (308)
Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease (2004) (305)
Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis (2010) (304)
BACE1 regulates voltage-gated sodium channels and neuronal activity (2007) (303)
Mild head injury increasing the brain's vulnerability to a second concussive impact. (2001) (303)
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease (1995) (300)
Detection of a Novel Intraneuronal Pool of Insoluble Amyloid β Protein that Accumulates with Time in Culture (1998) (297)
Comparison of family histories in FTLD subtypes and related tauopathies (2005) (288)
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. (2008) (287)
PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus (2001) (285)
Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice (2016) (275)
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI (2011) (275)
Neuropathology of synuclein aggregates (2000) (274)
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia (1998) (274)
Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. (1998) (272)
Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration (2005) (271)
Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. (2008) (269)
Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. (2009) (269)
Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration (2015) (266)
Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. (1999) (265)
Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. (2002) (265)
Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. (2003) (264)
Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy (2010) (264)
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. (2012) (260)
Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. (2000) (257)
Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice (2002) (252)
Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease (1999) (252)
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. (1996) (250)
Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. (2012) (250)
TDP-43 Mediates Degeneration in a Novel Drosophila Model of Disease Caused by Mutations in VCP/p97 (2010) (248)
Mutations in COQ2 in familial and sporadic multiple-system atrophy. (2013) (246)
Concurrence of α-synuclein and tau brain pathology in the Contursi kindred (2002) (243)
Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease (2002) (242)
Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain (2017) (235)
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. (2012) (233)
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. (2009) (232)
CSF biomarkers in frontotemporal lobar degeneration with known pathology (2008) (230)
Axonal Transport, Amyloid Precursor Protein, Kinesin-1, and the Processing Apparatus: Revisited (2005) (229)
Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. (1991) (229)
Altered Tau and Neurofilament Proteins in Neuro‐Degenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias (1993) (226)
TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. (2000) (226)
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. (2012) (225)
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease (2005) (225)
Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) (2014) (222)
Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases (1995) (220)
Are Ubiquitination Pathways Central to Parkinson's Disease? (2003) (219)
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders (2006) (214)
Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease (2001) (213)
A panel of epitope‐specific antibodies detects protein domains distributed throughout human α‐synuclein in lewy bodies of Parkinson's disease (2000) (212)
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. (2004) (211)
Induction of alpha-synuclein aggregation by intracellular nitrative insult. (2001) (211)
Expression of neurofilament subunits in neurons of the central and peripheral nervous system: an immunohistochemical study with monoclonal antibodies (1986) (211)
TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions (2007) (209)
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. (2012) (208)
TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease (2007) (205)
Phosphorylated α-Synuclein in Parkinson’s Disease (2012) (203)
An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype (2002) (202)
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) (202)
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine (2015) (201)
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. (2000) (200)
Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy (2011) (200)
Nitration of tau protein is linked to neurodegeneration in tauopathies. (2003) (197)
Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis (2012) (197)
Alpha-synuclein: normal function and role in neurodegenerative diseases. (2004) (197)
Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains (2015) (196)
Inducible expression of neuronal glutamate receptor channels in the NT2 human cell line. (1993) (196)
Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. (2001) (196)
Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary (2000) (195)
IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques (2002) (193)
Cognitive and motor assessment in autopsy-proven corticobasal degeneration (2007) (191)
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model (2007) (190)
An acetylation switch controls TDP-43 function and aggregation propensity (2015) (190)
Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy (2004) (189)
Phosphate dependent and independent neurofilament epitopes in the axonal swellings of patients with motor neuron disease and controls. (1987) (188)
TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord (2014) (187)
Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion (2012) (186)
Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases (2009) (183)
TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways (2012) (182)
TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. (2011) (182)
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. (2010) (182)
Transplanted human neurons derived from a teratocarcinoma cell line (NTera‐2) mature, integrate, and survive for over 1 year in the nude mouse brain (1995) (182)
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. (2008) (181)
TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. (2007) (180)
‘Unfolding’ pathways in neurodegenerative disease (2003) (179)
Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy (2018) (179)
More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases (2004) (178)
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. (2020) (177)
“Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders (2000) (176)
Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. (2001) (174)
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. (2010) (173)
Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43 (2015) (173)
Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP‐43 proteinopathies (2010) (172)
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases (2012) (171)
Calcium Entry and α-Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons (2013) (169)
Olfactory epithelium amyloid‐β and paired helical filament‐tau pathology in Alzheimer disease (2010) (169)
Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment (2010) (168)
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. (1991) (168)
The cytoskeleton in neurodegenerative diseases (2004) (167)
Pathological TDP-43 in parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam (2007) (167)
Distinct cerebral perfusion patterns in FTLD and AD (2010) (166)
Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s afferent and efferent connections (2015) (164)
Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies (2008) (164)
Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice (2015) (162)
Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. (2013) (162)
Parkin and the Molecular Pathways of Parkinson's Disease (2001) (161)
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (2001) (161)
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury (2004) (160)
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. (1996) (159)
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. (2008) (158)
Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration (2005) (158)
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy (2015) (157)
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. (1997) (156)
Redox signalling directly regulates TDP‐43 via cysteine oxidation and disulphide cross‐linking (2012) (156)
Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* (2003) (155)
Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. (2012) (153)
A distinct familial presenile dementia with a novel missense mutation in the tau gene. (1999) (153)
Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2 (2005) (151)
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease (2004) (150)
Sporadic Pick's disease: A tauopathy characterized by a spectrum of pathological τ isoforms in gray and white matter (2002) (149)
TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss (2017) (148)
Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies (2014) (148)
The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. (1994) (147)
Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. (1990) (146)
Distribution patterns of tau pathology in progressive supranuclear palsy (2020) (146)
β-Synuclein gene alterations in dementia with Lewy bodies (2004) (145)
Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses (2003) (144)
Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques (1997) (144)
DJ‐1 colocalizes with tau inclusions: A link between parkinsonism and dementia (2004) (144)
Selective Destruction of Stable Microtubules and Axons by Inhibitors of Protein Serine/Threonine Phosphatases in Cultured Human Neurons (NT2N Cells) (1997) (144)
Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of α‐Synuclein Permutations in Multiple System Atrophy (2000) (142)
The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. (2011) (141)
Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis (2012) (140)
Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. (1998) (140)
Modulation of Nuclear Factor-κB Activity by Indomethacin Influences Aβ Levels but Not Aβ Precursor Protein Metabolism in a Model of Alzheimer's Disease (2004) (140)
Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration (2002) (140)
TREM2 function impedes tau seeding in neuritic plaques (2019) (139)
Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation (2004) (138)
P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating (2011) (138)
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. (2002) (137)
Tau and axonopathy in neurodegenerative disorders (2002) (137)
Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. (2000) (135)
α‐synuclein is developmentally expressed in cultured rat brain oligodendrocytes (2000) (135)
Distinct cleavage patterns of normal and pathologic forms of α‐synuclein by calpain I in vitro (2003) (134)
Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. (1995) (133)
In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. (2000) (132)
Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model. (2005) (132)
Signature tau neuropathology in gray and white matter of corticobasal degeneration. (2002) (131)
Vascular disease and dementias: Paradigm shifts to drive research in new directions (2013) (131)
Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. (2014) (130)
Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders (2019) (130)
Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration (2017) (130)
TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading (2018) (130)
Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review (2019) (129)
Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders (1996) (128)
Lewy body pathology in Alzheimer’s disease (2001) (126)
Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques (1999) (126)
Even in culture, oligodendrocytes myelinate solely axons. (1993) (125)
Deep clinical and neuropathological phenotyping of Pick disease (2016) (124)
α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies (2019) (124)
Therapeutic strategies for tau mediated neurodegeneration (2012) (124)
Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous α-Synuclein Inclusions of α-Synucleinopathies (2006) (124)
In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders (2011) (123)
Neurons Derived from a Human Teratocarcinoma Cell Line Establish Molecular and Structural Polarity Following Transplantation into the Rodent Brain (1993) (122)
The microtubule-associated tau protein has intrinsic acetyltransferase activity (2013) (121)
Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. (1997) (121)
The Expression of α-, β-, and γ-Synucleins in Olfactory Mucosa from Patients with and without Neurodegenerative Diseases (1999) (120)
TDP-43 Proteinopathies: Neurodegenerative Protein Misfolding Diseases without Amyloidosis (2007) (120)
Expression patterns of β‐amyloid precursor protein (β‐APP) in neural and nonneural human tissues from alzheimer's disease and control subjects (1991) (119)
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions (2014) (119)
Nerve Growth Factor Induces Apoptosis in Human Medulloblastoma Cell Lines that Express TrkA Receptors (1997) (118)
Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. (2004) (118)
Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). (1992) (118)
Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models (2015) (118)
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. (2004) (118)
Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model (2007) (118)
RNA sequestration to pathological lesions of neurodegenerative diseases (1998) (116)
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. (2008) (115)
A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. (2007) (115)
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment (2005) (115)
Human olfactory epithelium in normal aging, alzheimer's disease, and other neurodegenerative disorders (1991) (115)
Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation* (2013) (115)
Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. (2004) (114)
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. (2011) (113)
Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. (2008) (113)
Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology (2016) (112)
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. (2013) (112)
α-Synuclein pathology spread through the brain connectome is modulated by selective vulnerability and predicted by network analysis (2019) (111)
Plasma apolipoprotein A1 as a biomarker for Parkinson disease (2013) (111)
An immunohistochemical study of human central and peripheral nervous system tumors, using monoclonal antibodies against neurofilaments and glial filaments. (1984) (110)
A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114 (2003) (110)
Intraneuronal APP, Not Free Aβ Peptides in 3xTg-AD Mice: Implications for Tau versus Aβ-Mediated Alzheimer Neurodegeneration (2011) (110)
Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes (2006) (109)
TDP-43: a novel neurodegenerative proteinopathy (2007) (109)
Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit (1986) (108)
Age-dependent synuclein pathology following traumatic brain injury in mice (2003) (108)
Accelerated Aβ Deposition in APPswe/PS1ΔE9 Mice with Hemizygous Deletions of TTR (Transthyretin) (2007) (108)
Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies (2005) (107)
Paired helical filament tau in Alzheimer's disease. The kinase connection. (1994) (107)
Epitopes located in spatially separate domains of each neurofilament subunit are present in parkinson's disease lewy bodies (1991) (107)
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. (2006) (107)
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology (2018) (106)
Primitive Neuroectodermal Tumors of the Central Nervous System (1997) (106)
A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. (2010) (104)
Tau and α-Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam (2002) (104)
Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease (2012) (104)
IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. (2001) (104)
Expression of trk receptors in the developing and adult human central and peripheral nervous system (1995) (104)
Transfectable and Transplantable Postmitotic Human Neurons: A Potential “Platform” for Gene Therapy of Nervous System Diseases (1997) (103)
Molecular milestones that signal axonal maturation and the commitment of human spinal cord precursor cells to the neuronal or glial phenotype in development (1991) (103)
Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies (2018) (103)
Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis (2011) (102)
Nosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire (2005) (101)
Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study (2018) (101)
Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies (2005) (101)
α-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies (2011) (100)
A90V TDP‐43 variant results in the aberrant localization of TDP‐43 in vitro (2008) (100)
Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis (2011) (100)
Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. (2006) (99)
Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein (1999) (99)
Modeling Lewy pathology propagation in Parkinson's disease. (2014) (99)
Acetylated tau neuropathology in sporadic and hereditary tauopathies. (2013) (98)
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. (2012) (98)
Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation (2000) (98)
Rapid and Intermittent Cotransport of Slow Component-b Proteins (2007) (98)
Neurodegenerative Tauopathies Human Disease and Transgenic Mouse Models (1999) (98)
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. (2011) (97)
Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia (2020) (97)
Variants associated with Gaucher disease in multiple system atrophy (2015) (97)
Phosphorylated alpha-Synuclein in Parkinson's Disease (2012) (96)
Interactions of amyloidogenic proteins (2007) (95)
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. (2010) (95)
The Chemokine Stromal Cell-Derived Factor-1 Promotes the Survival of Embryonic Retinal Ganglion Cells (2003) (94)
TDP-43 skeins show properties of amyloid in a subset of ALS cases (2012) (94)
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. (2007) (94)
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. (2005) (94)
High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. (2007) (94)
In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease (2000) (93)
Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits (1995) (93)
Axon pathology in Parkinson ’ s disease and Lewy body dementia hippocampus contains a-, b-, and g-synuclein (1999) (93)
Cerebral ischemia and CNS transplantation: differential effects of grafted fetal rat striatal cells and human neurons derived from a clonal cell line (1998) (93)
Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors (2010) (92)
Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology (2019) (91)
Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. (2014) (91)
Biomarkers for Early Detection of Alzheimer Pathology (2007) (90)
Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites (1993) (90)
Physical activity and cognitive health (2007) (90)
Brain Trauma in Aged Transgenic Mice Induces Regression of Established Aβ Deposits (2000) (90)
Genetically Modified NT2N Human Neuronal Cells Mediate Long‐Term Gene Expression as CNS Grafts In Vivo and Improve Functional Cognitive Outcome Following Experimental Traumatic Brain Injury (2003) (90)
PolyQ Repeat Expansions in ATXN2 Associated with ALS Are CAA Interrupted Repeats (2011) (89)
Twofold overexpression of human β‐amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury (1998) (89)
Survival profiles of patients with frontotemporal dementia and motor neuron disease. (2009) (89)
Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells (2000) (88)
Beta-synuclein gene alterations in dementia with Lewy bodies. (2004) (88)
Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). (2007) (87)
Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease (2007) (87)
Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer's disease senile plaque neurites and neuropil threads. (1991) (87)
Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease (1994) (86)
Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains (1998) (85)
Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats. (1999) (85)
Pathological tau: a loss of normal function or a gain in toxicity? (2005) (85)
Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors (1996) (85)
Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases (2017) (84)
Differential Expression and Distribution of α-, β-, and γ-Synuclein in the Developing Human Substantia Nigra (2001) (84)
Characterization and differential distribution of the three major human protein kinase C isozymes (PKC alpha, PKC beta, and PKC gamma) of the central nervous system in normal and Alzheimer's disease brains. (1991) (84)
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis (2004) (83)
Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production (2017) (83)
Long‐term integration and neuronal differentiation of human embryonal carcinoma cells (NT era‐2) transplanted into the caudoputamen of nude mice (1996) (83)
White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration (2013) (82)
Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. (2011) (82)
Amyloid binding ligands as Alzheimer’s disease therapies (2002) (82)
Effects of α-tocopherol on an animal model of tauopathies (2004) (81)
17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. (2004) (81)
Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia (2003) (81)
The North American Multiple System Atrophy Study Group (2005) (80)
Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies (2014) (80)
Ex vivo gene therapy using targeted engraftment of NGF-expressing human NT2N neurons attenuates cognitive deficits following traumatic brain injury in mice. (2004) (80)
Microtubule stabilizing drugs for the treatment of Alzheimer's disease (1994) (79)
A new link between pesticides and Parkinson's disease (2000) (79)
Disruption of the cytoskeleton in Alzheimer's disease (1995) (78)
Expression of neuronal and glial polypeptides during histogenesis of the human cerebellar cortex including observations on the dentate nucleus (1993) (78)
Pathobiology of the Lewy body. (1999) (78)
Proteasome Inhibition Stabilizes Tau Inclusions in Oligodendroglial Cells that Occur after Treatment with Okadaic Acid (2003) (78)
Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology (2018) (78)
Tau Proteins Are Abnormally Expressed in Olfactory Epithelium of Alzheimer Patients and Developmentally Regulated in Human Fetal Spinal Cord (1993) (78)
Molecular markers of primitive neuroectodermal tumors and other pediatric central nervous system tumors. Monoclonal antibodies to neuronal and glial antigens distinguish subsets of primitive neuroectodermal tumors. (1989) (78)
A comparison of eight different chromogen protocols for the demonstration of immunoreactive neurofilaments or glial filaments in rat cerebellum using the peroxidase-antiperoxidase method and monoclonal antibodies. (1983) (77)
Longitudinal decline in autopsy-defined frontotemporal lobar degeneration (2008) (77)
Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration (2016) (77)
Immunological and conformational characterization of a phosphorylated immunodominant epitope on the paired helical filaments found in Alzheimer's disease (1992) (77)
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges (2016) (77)
Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments (2001) (77)
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. (2004) (77)
Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment (2000) (77)
-synuclein modulates -synuclein neurotoxicity by reducing -synuclein protein expression (2006) (76)
The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. (2001) (76)
Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. (1990) (76)
Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. (2014) (76)
Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer's disease with injury to pedunculopontine cholinergic neurons. (2005) (75)
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. (2003) (75)
Transmission of tauopathy strains is independent of their isoform composition (2019) (75)
Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs (2017) (75)
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. (2007) (73)
Reduction of Detyrosinated Microtubules and Golgi Fragmentation Are Linked to Tau-Induced Degeneration in Astrocytes (2003) (73)
Neuronal origin of human esthesioneuroblastoma demonstrated with anti-neurofilament monoclonal antibodies. (1982) (72)
The disordered neuronal cytoskeleton in Alzheimer's disease (1992) (72)
The neuropathology of dementia (2004) (71)
Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. (2009) (71)
Aggregation of α-Synuclein in S. cerevisiae is Associated with Defects in Endosomal Trafficking and Phospholipid Biosynthesis (2011) (70)
Proliferation, cell death, and neuronal differentiation in transplanted human embryonal carcinoma (NTera2) cells depend on the graft site in nude and severe combined immunodeficient mice. (1995) (70)
Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons (2016) (70)
Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders (2018) (69)
TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system (2008) (69)
Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis (2018) (68)
In vivo measurement of plaque burden in a mouse model of Alzheimer's disease (2006) (68)
Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis (2016) (68)
Transmission of α-synuclein seeds in neurodegenerative disease: recent developments (2019) (68)
Brain progranulin expression in GRN-associated frontotemporal lobar degeneration (2009) (68)
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference (2014) (67)
Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. (2002) (67)
Analysis of epitopes shared by Hirano bodies and neurofilament proteins in normal and Alzheimer's disease hippocampus. (1989) (66)
Immunohistochemical application of monoclonal antibodies against myelin basic protein and neurofilament triple protein subunits: advantages over antisera and technical limitations. (1983) (66)
Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. (1990) (66)
Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments (2005) (66)
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult (2019) (65)
The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. (1999) (65)
Distribution of neurofilament subunits in neurons and neuronal processes: immunohistochemical studies of bovine cerebellum with subunit-specific monoclonal antibodies. (1985) (65)
A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex (2000) (64)
Astrocytic TDP-43 Pathology in Alexander Disease (2014) (63)
Biochemical Analysis of τ Proteins in Argyrophilic Grain Disease, Alzheimer's Disease, and Pick's Disease: A Comparative Study (2002) (63)
Building an integrated neurodegenerative disease database at an academic health center (2011) (63)
Selective Degeneration of Purkinje Cells with Lewy Body-Like Inclusions in Aged NFHLACZ Transgenic Mice (1997) (63)
Protein astrogliopathies in human neurodegenerative diseases and aging (2017) (62)
An English kindred with a novel recessive tauopathy and respiratory failure (2003) (62)
Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. (2012) (62)
Characterization of tau fibrillization in vitro (2010) (62)
Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. (1990) (62)
The role of tau in Alzheimer's disease. (2002) (62)
Molecular features of hypothalamic plaques in Alzheimer's disease. (1991) (62)
Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain (2018) (62)
Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. (2002) (61)
Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease (2006) (61)
Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. (1996) (60)
The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. (1990) (60)
The disordered neuronal cytoskeleton in Alzheimer's disease (1992) (60)
Olfactory dysfunction occurs in transgenic mice overexpressing human τ protein (2004) (60)
Introduction of nerve growth factor (NGF) receptors into a medulloblastoma cell line results in expression of high- and low-affinity NGF receptors but not NGF-mediated differentiation. (1990) (59)
A Novel Apoptotic Pathway Induced by Nerve Growth Factor-mediated TrkA Activation in Medulloblastoma* (2000) (58)
Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. (1996) (58)
Cell-to-Cell Transmission of Tau and α-Synuclein. (2020) (58)
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. (2007) (58)
Early fetal acquisition of the chromaffin and neuronal immunophenotype by human adrenal medullary cells. An immunohistological study using monoclonal antibodies to chromogranin A, synaptophysin, tyrosine hydroxylase, and neuronal cytoskeletal proteins (1990) (58)
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. (2007) (57)
Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease (1998) (57)
Traumatic brain injury in young, amyloid‐β peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Aβ deposition during aging (1999) (57)
Terminally differentiated human neurons survive and integrate following transplantation into the traumatically injured rat brain. (1999) (56)
Distribution of phosphate-independent MAP2 epitopes revealed with monoclonal antibodies in microwave-denatured human nervous system tissues (1989) (56)
Cortical biochemistry in MCI and Alzheimer disease (2007) (56)
Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. (2006) (56)
Human tau pathology transmits glial tau aggregates in the absence of neuronal tau (2019) (55)
Purification of paired helical filament tau and normal tau from human brain tissue. (1999) (55)
Spinal Cord Neurofibrillary Pathology in Alzheimer Disease and Guam Parkinsonism‐Dementia Complex (2001) (54)
Phosphorylation of Neuronal Cytoskeletal Proteins in Alzheimer's Disease and Lewy Body Dementias a (1994) (54)
Monoclonal antibodies to purified cortical lewy bodies recognize the mid‐size neurofilament subunit (1997) (54)
Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis (2005) (54)
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration (2022) (53)
Plasma biomarkers of depressive symptoms in older adults (2012) (53)
Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies (2018) (53)
Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. (1995) (53)
Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. (2003) (53)
Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration (2007) (53)
Cytoskeletal Requirements in Axonal Transport of Slow Component-b (2008) (52)
Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study (2003) (52)
α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases (2004) (51)
Neuronal modulation of schwann cell glial fibrillary acidic protein (GFAP) (1989) (51)
Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples (2019) (51)
Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy (2011) (50)
Effects of TNFα-Converting Enzyme Inhibition on Amyloid β Production and APP Processing In Vitro and In Vivo (2008) (50)
An extensive network of PHFτ‐rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease (1994) (50)
Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts. (1992) (49)
Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration (2014) (48)
The Dynamics and Turnover of Tau Aggregates in Cultured Cells (2016) (48)
Delayed transplantation of human neurons following brain injury in rats: a long-term graft survival and behavior study. (2005) (47)
Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible (2002) (47)
A Review and Rationale for the Use of Genetically Engineered Animals in the Study of Traumatic Brain Injury (2001) (47)
Expression of α-, β-, and γ-synuclein in glial tumors and medulloblastomas (2003) (47)
Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. (2010) (47)
Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. (1999) (47)
Prominent Perikaryal Expression of α- and β-Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons (2001) (47)
A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. (1998) (46)
The development and convergence of co-pathologies in Alzheimer's disease. (2020) (45)
Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain. (2001) (45)
Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease : a comparative study. (2002) (45)
Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease (1992) (45)
Poly-A Binding Protein-1 Localization to a Subset of TDP-43 Inclusions in Amyotrophic Lateral Sclerosis Occurs More Frequently in Patients Harboring an Expansion in C9orf72 (2014) (45)
β-Amyloid Peptide and Amyloid Precursor Proteins in Olfactory Mucosa of Patients with Alzheimer's Disease, Parkinson's Disease, and down Syndrome (1995) (45)
Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease (1992) (45)
Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy (2016) (44)
Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies (2016) (44)
Properties of antigenic determinants that distinguish neurofibrillary tangles in progressive supranuclear palsy and Alzheimer's disease. (1988) (44)
Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration (2007) (43)
Phosphate-dependent and independent neurofilament protein epitopes are expressed throughout the cell cycle in human medulloblastoma (D283 MED) cells. (1989) (43)
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. (2012) (43)
Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. (1999) (43)
Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. (2018) (43)
Progression of alpha‐synuclein pathology in multiple system atrophy of the cerebellar type (2017) (43)
New insights into genetic and molecular mechanisms of brain degeneration in tauopathies (2000) (42)
Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. (2006) (42)
Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT) (1999) (42)
Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. (1993) (42)
Novel conformation‐selective alpha‐synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease (2017) (42)
Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. (2003) (42)
Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex: Transgenic Mice Provide Insights into Mechanisms Underlying a Common Tauopathy in an Ethnic Minority on Guam (2002) (42)
Unexpected abundance of pathological tau in progressive supranuclear palsy white matter (2006) (41)
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations (2008) (41)
Neurofilament reassembly in vitro: biochemical, morphological and immuno-electron microscopic studies employing monoclonal antibodies to defined epitopes (1991) (41)
Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies. (2011) (40)
Nerve growth factor receptor expression in peripheral and central neuroectodermal tumors, other pediatric brain tumors, and during development of the adrenal gland. (1991) (39)
Neurobiology of human neurons (NT2N) grafted into mouse spinal cord: implications for improving therapy of spinal cord injury. (2000) (39)
Effects of alpha-tocopherol on an animal model of tauopathies. (2004) (39)
Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease. (2020) (39)
Monoclonal and polyclonal antibodies against neural antigens: diagnostic applications for studies of central and peripheral nervous system tumors. (1983) (39)
Iodinated tracers for imaging amyloid plaques in the brain. (2003) (39)
Lowering the risk of Alzheimer’s disease: Evidence-based practices emerge from new research (2005) (38)
Two distinct mechanisms of nitric oxide-mediated neuronal cell death show thiol dependency. (2000) (38)
Molecular Pathology of Alzheimer’s Disease and Related Disorders (1999) (38)
Expression patterns of beta-amyloid precursor protein (beta-APP) in neural and nonneural human tissues from Alzheimer's disease and control subjects. (1991) (38)
Neurofibrillary pathology and aluminum in Alzheimer's disease. (1995) (38)
C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy (2019) (38)
Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease (2018) (37)
Transgenic Models of Tauopathies and Synucleinopathies (1999) (37)
Semi-Automated Digital Image Analysis of Pick’s Disease and TDP-43 Proteinopathy (2016) (37)
Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors (1998) (37)
Individual neurofilament subunits reassembled in vitro exhibit unique biochemical, morphological and immunological properties (1991) (37)
Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia complex contain species of Aβ similar to those found in the amyloid plaques of Alzheimer’s disease and pathological aging (1998) (36)
Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study (2015) (36)
α-Synuclein modulates tau spreading in mouse brains (2020) (36)
Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions (2012) (36)
Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. (2001) (36)
Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy (2003) (36)
Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. (2020) (35)
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. (2013) (35)
Synphilin in normal human brains and in synucleinopathies: studies with new antibodies (2003) (35)
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies (2015) (34)
A novel modification of the avidin-biotin complex method for immunohistochemical studies of transgenic mice with murine monoclonal antibodies. (1992) (34)
Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. (1997) (34)
Selective Vulnerability of Mouse CNS Neurons to Latent Infection with a Neuroattenuated Herpes Simplex Virus-1 (1996) (34)
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases (2017) (33)
Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties. (2012) (33)
Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. (1998) (33)
Detection of amyloid plaques by radioligands for Aβ40 and Aβ42 (2003) (33)
The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates (2020) (32)
Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. (2001) (32)
Pathologic Changes in Olfactory Neurons in Alzheimer's Disease a (1991) (32)
Expression of neurofilament antigens by normal and neoplastic human adrenal chromaffin cells. (1985) (32)
Protein arginylation targets alpha synuclein, facilitates normal brain health, and prevents neurodegeneration (2017) (32)
An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline (2020) (31)
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons (2018) (31)
Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex (2006) (31)
Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain (2013) (31)
Forebrain overexpression of α-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption (2010) (31)
Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists. (2011) (30)
Thromboxane Receptor Activation Mediates Isoprostane-Induced Increases in Amyloid Pathology in Tg2576 Mice (2008) (30)
Dementia with Lewy bodies (1999) (29)
Rational design of an animal model for alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent (1996) (29)
α-Synuclein in Familial Alzheimer Disease: Epitope Mapping Parallels Dementia With Lewy Bodies and Parkinson Disease (2001) (29)
Human tau isoforms confer distinct morphological and functional properties to stably transfected fibroblasts. (1993) (29)
Frontotemporal dementia and tauopathy (2001) (29)
Monoclonal antibodies to a rat nestin fusion protein recognize a 220-kDa polypeptide in subsets of fetal and adult human central nervous system neurons and in primitive neuroectodermal tumor cells. (1993) (28)
Coordinate reduction in cell proliferation and cell death in mouse olfactory epithelium from birth to maturity (1997) (28)
Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTLD-TDP and ALS C9orf72 Expansion Cases (2015) (28)
Plaque-Associated Neuronal Proteins: A Recurrent Motif in Neuritic Amyloid Deposits throughout Diverse Cortical Areas of the Alzheimer's Disease Brain (1994) (28)
Co-occurrence of Parkinson's disease with progressive supranuclear palsy (2002) (28)
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease (2002) (27)
UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis (2019) (27)
Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. (2001) (27)
Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease. (1994) (27)
Connexin‐43 and aquaporin‐4 are markers of ageing‐related tau astrogliopathy (ARTAG)‐related astroglial response (2018) (27)
β-Secretase revealed: starting gate for race to novel therapies for Alzheimer’s disease (2000) (27)
Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease. (1999) (27)
Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease (1997) (26)
Increased levels of fucosyltransferase IX and carbohydrate Lewisx adhesion determinant in human NT2N neurons (2007) (26)
Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation (2004) (26)
Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. (2015) (26)
Antibodies to the β‐amyloid peptide cross‐react with conformational epitopes in human fibrinogen subunits from peripheral blood (1990) (26)
Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor (2021) (26)
Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. (2019) (26)
TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation (2012) (26)
The developmental expression of neurofilament and glial filament proteins in the human pituitary gland: an immunohistochemical study with monoclonal antibodies. (1984) (25)
Neurotrophin signal transduction in medulloblastoma (1997) (25)
Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration (2017) (25)
Human Olfactory Mucosa in Schizophrenia (1998) (25)
Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson's disease (2014) (25)
In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood (1994) (25)
Molecular phenotype of simian virus 40 large T antigen-induced primitive neuroectodermal tumors in four different lines of transgenic mice. (1994) (25)
Familial frontotemporal dementia: from gene discovery to clinical molecular diagnostics. (2003) (25)
Neurofilament breakdown products in degenerating rat and human peripheral nerves (1984) (25)
Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup. (2010) (25)
Design of comprehensive Alzheimer's disease centers to address unmet national needs (2010) (25)
Characterization of tau binding by gosuranemab (2020) (25)
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease (2019) (25)
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy (2018) (24)
A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model (2018) (23)
Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. (2006) (23)
A comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis (2014) (23)
Synucleinopathies: a pathological and molecular review (2001) (23)
Calcineurin Immunoreactivity in Alzheimer's Disease (1994) (23)
Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. (2017) (23)
Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. (1995) (23)
Human neurons that constitutively secrete Aβ do not induce Alzheimer's disease pathology following transplantation and long-term survival in the rodent brain (1995) (22)
Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice (2019) (22)
Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain (2019) (22)
Aβ immunization: Moving Aβ peptide from brain to blood (2001) (21)
alpha-Synuclein Pathology in Parkinson’s Disease and Related alpha-Synucleinopathies (2020) (21)
Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it. (2005) (21)
Reversible β-pleated sheet formation of a phosphorylated synthetic τ peptide (1992) (21)
Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease. (2012) (21)
Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue (2022) (21)
Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia (2014) (21)
Beta-Amyloid peptide and amyloid precursor proteins in olfactory mucosa of patients with Alzheimer's disease, Parkinson's disease, and Down syndrome. (1995) (21)
Modulation of antigenic expression in cultured adult human oligodendrocytes by derivatives of adenosine 3′,5′-cyclic monophosphate (1985) (21)
Converging Patterns of &agr;-Synuclein Pathology in Multiple System Atrophy (2018) (20)
Transgenic mouse models of tauopathies: Prospects for animal models of Pick’s disease (2001) (20)
Neurofilament-Rich Intraneuronal Inclusions Exacerbate Neurodegenerative Sequelae of Brain Trauma in NFH/LacZ Transgenic Mice (2000) (20)
p38 Mitogen-activated Protein Kinase-independent Induction of gadd45 Expression in Nerve Growth Factor-induced Apoptosis in Medulloblastomas* (2001) (19)
Dynamics of cell proliferation and cell death during the emergence of primitive neuroectodermal tumors of the immature central nervous system in transgenic mice. (1995) (19)
Vulnerability of the neuronal cytoskeleton in aging and Alzheimer disease: widespread involvement of all three major filament systems. (1990) (19)
Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. (2018) (19)
Association of apolipoprotein ɛ4 allele and neuropathologic findings in patients with dementia (2004) (18)
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) (2019) (18)
Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. (2017) (17)
Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease (2009) (17)
Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. (2004) (17)
Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease (2021) (17)
Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils. (2019) (17)
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury (2004) (16)
Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor (2021) (16)
Molecular Identification of AMY, an Alzheimer Disease Amyloid‐Associated Protein (2003) (16)
Defining and predicting transdiagnostic categories of neurodegenerative disease (2019) (16)
Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. (2007) (16)
The use of mouse models to study cell-to-cell transmission of pathological tau. (2017) (16)
An immunocytochemical study of normal and abnormal human cerebrospinal fluid with monoclonal antibodies to glial fibrillary acidic protein. (1986) (15)
Tau epitopes in spinal cord neurofibrillary lesions in Chamorros of Guam (2000) (15)
Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains a (1996) (15)
Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. (2001) (15)
Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members (2016) (15)
Tau deposition patterns are associated with functional connectivity in primary tauopathies (2022) (14)
Exploring human/animal intersections: Converging lines of evidence in comparative models of aging (2008) (14)
Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. (2008) (14)
Brain degeneration linked to "fatal attractions" of proteins in Alzheimer's disease and related disorders. (2001) (14)
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research (2012) (14)
Expression of β-amyloid precursor protein in the developing human spinal cord (1994) (14)
Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice (2021) (13)
Hereditary tauopathies and idiopathic frontotemporal dementias (2004) (13)
Neural and neuroendocrine phenotype of neuroblastomas, ganglioneuroblastomas, ganglioneuromas and mature versus embryonic human adrenal medullary cells. (1991) (13)
Cognitive reserve in frontotemporal degeneration (2016) (13)
Molecular beam epitaxial growth of HgCdTe midwave infrared multispectral detectors (1998) (12)
Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice (2016) (12)
Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His (2015) (12)
Is the Initial Insult in Parkinson's Disease and Dementia with Lewy Bodies a Neuritic Dystrophy? (2003) (12)
Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late-life dementia (2006) (11)
Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro (2021) (11)
Tauopathy with hippocampal 4‐repeat tau immunoreactive spherical inclusions: a report of three cases (2018) (11)
Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples (2021) (11)
Selective expression of epitopes in multiphosphorylation repeats of the high and middle molecular weight neurofilament proteins in Alzheimer neurofibrillary tangles. (1989) (11)
Anti-neurofilament monoclonal antibodies: Reagents for the evaluation of human neoplasms (2004) (11)
Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery (2021) (11)
In situ blood-brain barrier permeability of a C-10 paclitaxel carbamate. (2008) (11)
Presence of an alpha-melanocyte-stimulating hormone-like epitope in the 150,000 dalton neurofilament subunit from diverse regions of the central nervous system: an immunohistochemical and immunoblot study in guinea pig. (1985) (11)
Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders (2000) (10)
Expression of vimentin, glial filament, and neurofilament proteins in primitive childhood brain tumors (1985) (10)
Constitutive expression of the mature array of neurofilament proteins by a CNS neuronal cell line (1991) (10)
Tau proteins and their significance in the pathobiology of Alzheimer's disease (1995) (10)
Diseases: New Concepts of Pathogenesis and Their Therapeutic Implications (2006) (10)
Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor‐predominant neurodegeneration with brain iron accumulation (2006) (10)
Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. (2003) (10)
Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual (2007) (10)
University of Dundee TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse (9)
Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497 (2014) (9)
AMY plaques in familial AD (2000) (9)
Pathobiological features in neurodegenerative diseases: an overview (2004) (9)
Neocortical β-amyloid area is associated with dementia and APOE in the oldest-old (2013) (9)
Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. (2021) (9)
The Alzheimer's Brain (2005) (9)
Spatial relationship of AMY protein deposits and different species of Abeta peptides in amyloid plaques of the Alzheimer disease brain. (1999) (8)
Meeting summary--cell biology of Parkinson's disease and related neurodegenerative disorders. (2003) (7)
Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays (2020) (7)
Dopamine neurons exhibit emergent glutamatergic identity in Parkinson's disease. (2021) (7)
Microtubule-Stabilizing Agents for Alzheimer’s and Other Tauopathies (2016) (7)
Correction of microtubule defects within Aβ plaque‐associated dystrophic axons results in lowered Aβ release and plaque deposition (2020) (7)
Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group. (2014) (7)
Genetic predictors of survival in behavioral variant frontotemporal degeneration (2019) (7)
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice (2020) (7)
Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges? (2019) (7)
Conformational change of a synthetic amyloid analogue des[Ala21,3O]A42 upon binding to octyl glucoside micelles (2004) (7)
Short Communication Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by a -, b -, and g -Synuclein Neuropathology (2000) (6)
Schizophrenia and its dementia (2004) (6)
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice (2020) (6)
Common threads in neurodegenerative disorders of aging (2006) (6)
Erratum to: Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) (2015) (6)
Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists. (2014) (5)
Burden of Neurodegenerative Diseases in a Cohort of Medical Examiner Subjects * (2010) (5)
Immunochemical detection of diverse molecular species of horseradish peroxidase recovered from rat superior cervical ganglion following retrograde transport (1985) (5)
Expression of beta-amyloid precursor protein in the developing human spinal cord. (1994) (5)
LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons (2021) (5)
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization (2022) (4)
Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. (2020) (4)
Drug discovery in neurodegenerative diseases. (2005) (4)
Increased isoprostane biosynthesis in alzheimer's disease: Correlation of a specific non invasive index of lipid peroxidation with disease severity (2000) (4)
INTRACEREBRAL INJECTION OF PREFORMED SYNTHETIC TAU FIBRILS INITIATES WIDESPREAD TAUOPATHY AND NEURONAL LOSS IN THE BRAINS OF TAU TRANSGENIC MICE (2014) (4)
Comparison of Cerebrospinal Fluid Levels of Tau and A 1-42 in Alzheimer's Disease and Frontotemporal Degeneration Using Two Analytical Platforms (P02.055) (2012) (4)
Plasma Apolipoprotein A 1 as a Biomarker for Parkinson ' s Disease (2013) (4)
Animal models of neurodegenerative dementing disorders other than Alzheimer's disease (2004) (4)
Mechanisms of Neuron Death in Neurodegenerative Diseases of the Elderly (1998) (4)
Neurodegenerative Diseases: Frontotemporal dementia with parkinsonism linked to Chromosome 17 (2005) (3)
Primitive neuroectodermal tumors (PNETs) of the CNS and PNS that express functional nerve growth factor receptors (NGFR) but fail to differentiate in response to NGF. (1991) (3)
Neuropathologic substrates of Parkinson's disease dementia (S52.002) (2012) (3)
Commentary on “Diagnosis of Alzheimer's disease: Two decades of progress” Alzheimer's disease research: New opportunities for early diagnosis and drug discovery (2005) (3)
Biochemistry of neurodegeneration [2] (multiple letters) (2001) (3)
Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy (2018) (3)
Direct extracellular electrical stimulation influences density dependent aggregation of fetal rat cerebrocortical neurons in vitro (1988) (3)
Novel probes for imaging amyloid: Iodinated benzothiazole derivatives (2001) (3)
Tau and α-Synuclein in Neurodegenerative Diseases (2001) (3)
Short Communication Full-Length Amyloid-f3(1-42(43)) and Amino-Terminally Modified and Truncated Amyloid-(42(43) Deposit in Diffuse Plaques (2007) (3)
Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. (2020) (3)
Alzheimer disease A68 proteins injected into rat brain induce codeposits of j8-amyloid, ubiquitin, and al-antichymotrypsin (tau/senile (2005) (3)
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice (2019) (3)
The Neuropathology of Dementia: Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with α-synuclein inclusions (2004) (3)
Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain (2013) (2)
Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex (2020) (2)
Defined neurofilament , T , and fi-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques ( cytoskeletal proteins / A 4 protein / neurodegenerative disease ) (2)
Tau pathology spreads between anatomically-connected regions of the brain and is modulated by a LRRK2 mutation (2020) (2)
Supporting Online Material for Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (2006) (2)
Redox signaling directly regulates TDP-43 via cysteine oxidation and disulfide cross-linking (2011) (2)
Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis (2022) (2)
Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons (2014) (2)
Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein (2023) (2)
Erratum: Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2 (Journal of Neuroscience (January 19, 2005) (689-698)) (2005) (2)
Purification of Lewy Bodies and Identification of α-Synuclein as a Major Component of Lewy Bodies (2000) (2)
Practical approach to pathological diagnosis (2004) (2)
Absence of C 9 ORF 72 expanded or intermediate repeats in autopsy confirmed Parkinson Disease (2014) (2)
THE IMMUNOPHENOTYPE OF CENTRAL PRIMITIVE NEUROECTODERMAL TUMORS (PNETS): 174 (1989) (2)
Neurodegenerative Diseases: Frontotemporal lobar degeneration (2005) (1)
P3-093: Characterization of CSF Aβ1-42, Tau and p-Tau181p concentrations at baseline in Alzheimer's disease neuroimaging initiative study patients (2008) (1)
Single-nuclei isoform RNA sequencing reveals combination patterns of transcript elements across human brain cell types (2021) (1)
Tau focused drug discovery for Alzheimer’s disease and related Neurodegenerative Tauopathies (2006) (1)
Neuroimaging-Based Staging of Pathological Spread in Patients with Known Tau Pathology (P4.085) (2015) (1)
Alzheimer’s Disease, Parkinson’s Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding (2008) (1)
Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration (2017) (1)
Pathogenesis of dementia: updating the role of synuclein pathology in sporadic and hereditary Alzheimer’s disease (2001) (1)
Phiel et al. reply (2011) (1)
PERFORMANCE EVALUATION OF NEW ABSORBANCE-BASED ELISAS FOR MEASURING DIFFERENT ALPHA-SYNUCLEIN (A-SYN) SPECIES IN CSF AND PLASMA (2016) (1)
Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. (2023) (1)
CEREBROSPINAL FLUID LEVELS OF AMYLOID BETA AND TAU AS ENDOPHENOTYPES REVEAL NOVEL VARIANTS POTENTIALLY INFORMATIVE FOR ALZHEIMER'S DISEASE (2016) (1)
Studies of a Human Neuron-Like Cell Line in Stroke and Spinal Cord Injury (2003) (1)
Clinical and Survival Profiles of Patients with Frontotemporal Dementia and Motor Neuron Disease (2009) (1)
O1-04-01 Transgenic mouse models of TAU pathology in astrocytes leading to nervous system degeneration (2004) (1)
P4-426 Effect of chronic lithium treatment on an animal model of tauopathies (2004) (1)
A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model (2018) (1)
S3-03-05: Tau focused drug discovery for Alzheimer's disease and related tauopathies (2008) (1)
Axonal Transport and Neurodegenerative Diseases (2009) (1)
Mutations of Human Cu, Zn Superoxide Dismutase Expressed in Transgenic Mice Cause Motor Neuron Disease (1996) (1)
Identification of an Abnormal Phosphorylation Site in Alzheimer's Disease Paired Helical Filaments Using Synthetic Peptides, (1992) (1)
P2-112 Selective suppression of NF-κB by indomethacin modulates Aβlevels and deposition but not metabolism in a model of Alzheimer disease (2004) (1)
Morphometric methods and dementia (2004) (1)
Abundant copathologies of polyglucosan bodies, frontotemporal lobar degeneration with TDP‐43 inclusions and ageing‐related tau astrogliopathy in a family with a GBE1 mutation (2022) (1)
Association of the MAPT with Cerebrospinal Fluid Phosphorylated Tau Levels in Frontotemporal Degeneration (S38.008) (2014) (1)
Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome (2021) (1)
Animal Models of Cerebral Ischemia (1998) (1)
Transgenic mice overexpressing the shortest human tau isoform develop a progressive tauopathy (2001) (1)
Transmission of alpha-synuclein in Parkinson’s disease (2013) (1)
Tau focused drug discovery for Alzheimer's disease and related tauopathies (2010) (1)
Transgenic mouse models of neurodegenerative disease (2004) (1)
Chapter 11 – Microtubule Stabilization (2016) (1)
ER stress in Alzheimer's disease and PSP: Common disease mechanism? (2012) (1)
Distinct Tau Gene Mutations Induce Specific Dysfunctions/Toxic Properties in Tau Proteins Associated With Specific FTDP-17 Phenotypes (2000) (1)
The Association for Frontotemporal Dementias (2009) (1)
Frontotemporal Dementias: Genotypes and Phenotypes (2005) (1)
The neuropathology of neurodegeneration with brain iron accumulation, type 1 (NBIA 1) contains insoluble α-synuclean (2000) (0)
Tau Phosphorylation and Dephosphorylation in the Pathogenesis of Alzheimer’s Disease (1996) (0)
Increased Cerebrospinal Fluid Total-Tau Levels in Hereditary Behavioral-Variant Frontotemporal Dementia (P5.030) (2015) (0)
CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE (2017) (0)
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons (2018) (0)
Survey of AMD and Normal Maculas for Amyloid-Beta Containing Vesicles (2003) (0)
The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease (2013) (0)
Alpha-Synuclein aggregate formation in oligodendroglia OLN-t40 cells stably transfected with alpha-Synuclein (2007) (0)
Multiphosphorylated synthetic peptides as antigens and immunogens in Alzheimer’s disease paired helical filaments (2002) (0)
Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy (2016) (0)
In Vivo T 1ρ -weighted MRI of Amyloid Transgenic Mouse Model of Alzheimer's Disease A B C (2003) (0)
A neuroattenuated ICP 34 . 5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system (1998) (0)
Biochemical Analysis of (cid:1) Proteins in Argyrophilic Grain Disease, Alzheimer’s Disease, and Pick’s Disease A Comparative Study (2002) (0)
APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease (2011) (0)
Tau Gene Mutations in FTDP-17 Syndromes (2007) (0)
THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER’S DISEASE PATHOLOGY (2018) (0)
P2-058 Synapse loss is an early pathological manifestation in a tauopthy model, P301S mutant tau transgenic mice (2004) (0)
The Abeta Oligomer Selective Antibody Nab61 Recognizes Abeta Oligomers In The AD And APP Transgenic Mouse Brains And Neutralizes Abeta Mediated Synaptic Dysfunction (2009) (0)
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease (2020) (0)
O4-06-01 α-Internexin is present in the hallmark lesions of neuronal intermediate filament inclusion disease (2004) (0)
Genetic & Neuroanatomic Associations in Sporadic Frontotemporal Lobar Degeneration (I5-1.002) (2014) (0)
TDP-43 and beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration (2009) (0)
Distinct biological activity of Lewy body α-Synuclein strain in mice (2023) (0)
Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice (2016) (0)
Parkinson's disease dementia: at the crossroads of α-synuclein, tau and amyloid-β (2014) (0)
Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice (2021) (0)
BOOK REVIEWS The Neuropathology of Dementia, 2nd Edition (2005) (0)
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy (2018) (0)
FIRST TAU, THEN NEUROFILAMENT EPITOPES APPEAR IN ALZHEIMER NEUROFIBRILLARY PATHOLOGY: 86 (1989) (0)
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization (2022) (0)
Impact of Single Amino Acid Modifications of Adeno-Associated Virus (AAV) Capsid and Viral Dose on Transduction Patterns After Transuterine Subretinal Delivery of AAV Vectors to the Fetal Retina (2009) (0)
Mechanisms of slow axonal transport of α-synuclein: 48.2 (2007) (0)
Featured Articles Improved protocol for measurement of plasma b-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients (2012) (0)
Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease (2022) (0)
Subject Index Vol. 6, 2009 (2010) (0)
Synuclein-Mitochondrial Interactions in Substantia Nigra Dopamine Neurons (2014) (0)
Vulnerability of the Neuronal Cytoskeleton in Aging and Alzheimer Disease: Widespread Involvement of All Three Major Filament Systems (1990) (0)
Intermediate Repeats Confer Risk for Corticobasal Degeneration and Increase C 9 orf 72 Expression (2020) (0)
Quantitative digital image analysis of Pick’s disease neuropatholgy (P5.012) (2015) (0)
TDP‐43 immunoreactivity in anoxic, ischemic and proliferating lesion of the central nervous system (2008) (0)
O4-06-02 TDP-43 AND BETA-AMYLOID PRECURSOR PROTEIN PROCESSING PRODUCTS IN CEREBROSPINAL FLUID OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL LOBAR DEGENERATION (0)
CELL-TO-CELL TRANSMISSION OF PATHOLOGICAL TAU: A POTENTIAL MECHANISM OF DISEASE PROGRESSION IN ALZHEIMER'S AND OTHER TAUOPATHIES (2017) (0)
Phosphorylated Tau Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis (P1.088) (2014) (0)
Degradative organelles containing mislocalized (cid:1) - and (cid:2) -synuclein proliferate in presenilin-1 null neurons (2004) (0)
Clinical and Biochemical Differences between Parkinson's Disease Patients With and Without Mutations in the Glucocerebrosidase Gene (P06.072) (2012) (0)
Genetic Influences of Survival in the Behavioral Variant of Frontotemporal Degeneration (P4.014) (2014) (0)
O2-06-04 Assessment of pathological tau proteins in new patients with R406W mutation in the tau gene (2004) (0)
P1-389 Increase of 12/15 lipooxygenase AD: potential role in oxidative stress (2004) (0)
Authors' response to commentaries (1995) (0)
S1-01-06 Intracellular and secreted neuronal amyloid beta peptides in AD (2004) (0)
AMYLOID PLAQUES IN GUAM AMYOTROPHIC LATERAL SCLEROSIS/AND PARKINSONISM-DEMENTIA COMPLEX (ALS/PDC) CONTAIN SPECIES OF Aβ SIMILAR TO THOSE FOUND IN THE AMYLOID PLAQUES OF ALZHEIMERʼS DISEASE (AD) AND PATHOLOGICAL AGING (PA) (1998) (0)
Contents Vol. 6, 2009 (2010) (0)
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies (2018) (0)
Regional analysis of abnormal tau protein distribution in progressive supranuclear palsy (2000) (0)
Radioiodinated styrylbenzene derivatives as probes for imaging amyloid (2001) (0)
Pathobiology of tauopathies: In vitro and in vivo models (2000) (0)
Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery (2021) (0)
Aminobenzothiazoles as inhibitors of tau-fibril formation in Alzheimer's and other neurodegenerative diseases (2008) (0)
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease (2019) (0)
P2-098: Comparison of diagnostics values of cerebrospinal fluid tau and structural magnetic resonance imaging in classifying patients with Alzheimer's disease versus normal subjects (2008) (0)
Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro (2021) (0)
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies (2015) (0)
Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins (2014) (0)
SYNUCLEIN IMMUNOREACTIVITY IN OLFACTORY EPITHELIUM AS A BIOMARKER FOR NEURODEGENERATIVE DISEASE (1999) (0)
BACE overexpression alters the subcellular processing of APP and inhibits A (cid:1) deposition in vivo (2005) (0)
Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
AM-02 Tau focused therapies: Overview (2007) (0)
P4-004 Microdialysis reveals β-amyloid levels in brain interstitial fluid regulated by γ-secretase and neprilysin inhibitors as well as overexpression of β-secretase in vivo (2006) (0)
α-Synuclein nitration in neuropathological inclusions (2000) (0)
Improving Diagnostic Accuracy for Dementia: CSF Biomarker Cutoffs Based on Clinical and Neuropathological Criteria (IN3-1.010) (2012) (0)
Multiplex plasma panels as screening tools in Alzheimer's disease. (2010) (0)
High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration (2015) (0)
P-057 Validation of the xMAP technology and performance of INNO-BIA AlzBio3 for quantification in CSF of Aβ1-42, total tau and P-tau181p (2007) (0)
Animal Models of Cerebral Ischemia: Neurodegeneration and Cell Transplantation (1998) (0)
EXPRESSION OF TRK-C RECEPTORS IN PRIMITIVE NEUROECTODERMAL TUMOR/ MEDULLOBLASTOMA CORRELATES WITH THE EXPRESSION OF NEUROFILAMENT PROTEINS AND IS ASSOCIATED WITH FAVORABLE PROGNOSIS (1999) (0)
Transmission of misfolded proteins in neurodegenerative disorders: a common mechanism of disease progression (2016) (0)
Human and rodent A4 peptides exhibit environment-dependent conformational differences (1993) (0)
Deep Clinical and Neuropathological Phenotyping of Pick’s Disease (S39.001) (2016) (0)
Representative immunofluorescence histological findings of tauopathy model mice and wild type mice. (2011) (0)
Longitudinal Cognitive Performance and Cerebrospinal Fluid Biomarkers in Sporadic and Hereditary Frontotemporal Lobar Degeneration (P05.102) (2013) (0)
THE BIOLOGICAL EFFECTS OF TRK RECEPTORS ON HUMAN MEDULLOBLASTOMAS (MBS) (1998) (0)
The Role of Age and Genetic Markers on Cerebrospinal Fluid Tau Levels in Pathology-Confirmed Frontotemporal Degeneration (P1.219) (2015) (0)
The Schmitt symposium: The cytoskeleton and Alzheimer's disease an introduction (1995) (0)
α-SYNUCLEIN IS A COMPONENT OF LEWY BODIES (1998) (0)
Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His (2015) (0)
Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain (2018) (0)
alpha-internexin is present in the hallmark lesions of neuronal intermediate filament inclusion disease (2004) (0)
Investigating key factors underlying neurodegeneration linked to alpha‐synuclein spread (2022) (0)
Mechanisms of slow axonal transport of {alpha}-synuclein (2007) (0)
Subpial Thorn-shaped Astrocytes Are Prevalent In Guam ALS/PDC (2021) (0)
Appendix: Dementia brain banks (2004) (0)
Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis (2022) (0)
O2-01-03 Impaired glutamate transport and excitotoxicity in a mouse model of tau pathology in astrocytes (2006) (0)
NEURONAL LOSS AND CYTOSKELETAL PERTURBATION AFTER TRAUMATIC BRAIN INJURY (TBI) IN THE NFH/LacZ TRANSGENIC MOUSE (1998) (0)
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Virginia M.‐y. Lee?

Virginia M.‐y. Lee is affiliated with the following schools:

University of Pennsylvania